Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overview
Explore Bristol-Myers Squibb Company Ce’s financial performance, market position, analyst ratings, and future outlook.
Bristol-Myers Squibb Company Ce (CELG-RI)
Key Financials
Key Financials
Market Cap
128.4B
P/E Ratio
13.88
EPS (TTM)
N/A
ROE
0.44%
CELG-RI Stock Analysis & Investment Overview (NYSE)
Our AI-powered analysis of Bristol-Myers Squibb Company Ce (NYSE: CELG-RI) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Bristol-Myers Squibb Company Ce's NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CELG-RI on the NYSE shows an RSI of 51.95, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.15 for the NYSE listing.
Key metrics behind Bristol-Myers Squibb Company Ce's NYSE-traded stock include a P/E ratio of 13.88 and a market capitalization of 128.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CELG-RI on the NYSE.